Title : Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.

Pub. Date : 2018 Feb

PMID : 29166791






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Areas covered: The application claims novel substituted benzothiadiazine derivatives as CD73 inhibitors for the treatment of cancer, precancerous syndromes, AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Benzothiadiazines 5'-nucleotidase ecto Homo sapiens
2 Expert Opinion: These benzothiadiazine derivatives provide good leads for the discovery of potent CD73 inhibitors for the treatment of cancer and other diseases mediated by adenosine and its action on adenosine receptors. Benzothiadiazines 5'-nucleotidase ecto Homo sapiens